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Abstract
Background Stereotactic body radiation therapy (SBRT) has emerged as a popular alternative to
conventional radiation therapy (RT) over the past 15 years. Unfortunately, the impact of patient
distance from radiation treatment centers and utilization of SBRT versus conventional RT has been
sparsely investigated. This report represents the first analysis of the impact of patient distance on
radiation treatment modality for central nervous system (CNS) disease.
Materials and Methods Since the inception of our RADIation oncology And Neuro-Surgery
(RADIANS) multidisciplinary clinic at a community hospital in 2016, 27 patients have received either
SBRT or conventional RT as their sole radiation treatment modality for CNS disease. Twenty-four
(88.9%) presented with metastatic disease. Fisher’s exact test evaluated the relationship between
patient residence from treatment (in miles) and radiation treatment modality received.
Results Mean patient distance from our RADIANS clinic was 50.6 miles (median = 15.3). Twenty-one
patients (77.8%) received SBRT; the remaining six received conventional RT. Mean patient distance
from SBRT was 63.6 miles, and mean patient distance for conventional RT was 5.1 miles; this finding
was statistically significant ( p = 0.0433; 95% confidence interval = 1.9–115.1).
Conclusion Our findings indicate that patients with CNS disease who receive SBRT over conventional
RT are statistically more likely to reside further from treatment centers. This is similar to findings of
national studies comparing proton versus photon treatment for pediatric solid malignancies. The results
from our work have implications for neuro-oncology treatment and the development of community
hospital-based clinic models similar to RADIANS in the future.
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Introduction
The increasing popularity of stereotactic body radiation therapy (SBRT) as an alternative to
conventional radiation therapy (RT) has permeated oncology over the past 15 years.   
Unfortunately, the impact of patient distance from radiation treatment centers and utilization of SBRT
versus conventional RT has been sparsely investigated; a recent report investigating localized prostate
cancer found that patients residing more than 25 miles from treatment centers were significantly more
likely to receive SBRT than conventional fractionation.  For patients receiving treatment in a
community hospital setting, this distance may play a significant role in treatment; many patients reside
more than 50 miles away from their nearest treatment center, with some residing more than 250 miles
away. This report represents the first analysis of the impact of patient distance on radiation treatment
modality for central nervous system (CNS) disease.
Materials and Methods
Since the inception of our RADIation oncology And NeuroSurgery (RADIANS) multidisciplinary
clinic at a community hospital in 2016, 27 patients have received either SBRT or conventional RT as
their sole radiation treatment modality for CNS disease; the radiation treatment center is located in the
same building as the clinic.  Twenty-four of these patients (88.9%) presented with metastatic disease
of the brain or spine. Of these 24 patients, 12 had brain metastases, 11 had spine metastases, and 1 had
both brain and spine metastases. Statistical analyses were performed using t -tests to evaluate the
relationship between patient residence from treatment (in miles), and radiation treatment modality
received, with statistical significance assigned at p < 0.05 (GraphPad Software, San Diego, California,
United States).
Results
Mean patient age was 64.4 (median = 67). Mean patient distance from our RADIANS clinic was 50.6
miles (median = 15.3). Fifteen patients resided < 25 miles away from clinic; eight were 51 to 100 miles
away, two were 101 to 200 miles away, and two were 200+ miles away from treatment. Twenty-one of
the 27 patients received SBRT (77.8%); the remaining six received conventional RT. Mean patient
distance from SBRT was 63.6 miles (standard error of mean [SEM] = 14.5), while for conventional RT
mean patient distance from treatment was 5.1 miles (SEM = 1.9); this finding was statistically
significant ( p = 0.0433; 95% confidence interval = 1.9–115.1).
Conclusion
As recently reported for localized prostate cancer,  our findings indicate that patients with CNS
disease who receive SBRT over conventional RT are statistically more likely to reside further from
treatment centers. This is similar to findings of national studies comparing proton versus photon
treatment for pediatric solid malignancies, where patients receiving proton therapy were significantly
more likely to travel > 200 miles to do so.  Unlike for prostate and breast cancer, for CNS disease
there is not Level I evidence establishing hypofractionation as equivalent to conventional RT; it is more
likely that the paucity of SBRT access in the treatment of brain/spine disease is the catalyst for our
distance-related findings.   The results from our work have implications for neuro-oncology
treatment and the development of community hospital-based clinic models similar to RADIANS in the
future. Further multicenter analyses will be warranted to determine whether the findings from this
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